24 reports of this reaction
1.9% of all CANDIDA ALBICANS reports
#8 most reported adverse reaction
GAIT DISTURBANCE is the #8 most commonly reported adverse reaction for CANDIDA ALBICANS, manufactured by DNA Labs, Inc.. There are 24 FDA adverse event reports linking CANDIDA ALBICANS to GAIT DISTURBANCE. This represents approximately 1.9% of all 1,258 adverse event reports for this drug.
Patients taking CANDIDA ALBICANS who experience gait disturbance should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
GAIT DISTURBANCE is a less commonly reported adverse event for CANDIDA ALBICANS, but still significant enough to appear in the safety profile.
In addition to gait disturbance, the following adverse reactions have been reported for CANDIDA ALBICANS:
The following drugs have also been linked to gait disturbance in FDA adverse event reports:
GAIT DISTURBANCE has been reported as an adverse event in 24 FDA reports for CANDIDA ALBICANS. This does not prove causation, but indicates an association observed in post-market surveillance data.
GAIT DISTURBANCE accounts for approximately 1.9% of all adverse event reports for CANDIDA ALBICANS, making it a notable side effect.
If you experience gait disturbance while taking CANDIDA ALBICANS, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.